Last reviewed · How we verify
Single-dose azithromycin
At a glance
| Generic name | Single-dose azithromycin |
|---|---|
| Sponsor | FHI 360 |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever (PHASE4)
- Improving Cognition and Gestational Duration With Targeted Nutrition (NA)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
- A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel (PHASE1)
- The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) (PHASE4)
- Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis (NA)
- Azithromycin and Ampicillin for Late PPROM (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single-dose azithromycin CI brief — competitive landscape report
- Single-dose azithromycin updates RSS · CI watch RSS
- FHI 360 portfolio CI